BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 30917791)

  • 1. Impact of primary colorectal Cancer location on the KRAS status and its prognostic value.
    Xie MZ; Li JL; Cai ZM; Li KZ; Hu BL
    BMC Gastroenterol; 2019 Mar; 19(1):46. PubMed ID: 30917791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
    Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
    Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS mutation status between left- and right-sided colorectal cancer: are there any differences in computed tomography?
    Yu MM; Shi D; Li Q; Li JB; Li Q; Yu RS
    Jpn J Radiol; 2023 Jan; 41(1):83-91. PubMed ID: 35976561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: An international, multi-institutional study in patients with known KRAS, BRAF, and MSI status.
    Kamphues C; Kadowaki S; Amini N; van den Berg I; Wang J; Andreatos N; Sakamoto Y; Ogura T; Kakuta M; Pikouli A; Geka D; Daitoku N; Theochari M; Buettner S; Akiyama T; Antoniou E; Pikoulis E; Theodoropoulos G; Imai K; Ijzermans JNM; Margonis GA; Akagi K; Kreis ME
    J Surg Oncol; 2021 Mar; 123(4):1005-1014. PubMed ID: 33368279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of
    Olmedillas-López S; Lévano-Linares DC; Alexandre CLA; Vega-Clemente L; Sánchez EL; Villagrasa A; Ruíz-Tovar J; García-Arranz M; García-Olmo D
    World J Gastroenterol; 2017 Oct; 23(39):7087-7097. PubMed ID: 29093617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of primary tumor sidedness on survival in early-onset colorectal cancer by stage: A National Veterans Affairs retrospective analysis.
    Azar I; Al Masalmeh N; Esfandiarifard S; Virk G; Kiwan W; Frank Shields A; Mehdi S; Philip PA
    Cancer Med; 2021 May; 10(9):2987-2995. PubMed ID: 33797856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.
    Maus MK; Hanna DL; Stephens CL; Astrow SH; Yang D; Grimminger PP; Loupakis F; Hsiang JH; Zeger G; Wakatsuki T; Barzi A; Lenz HJ
    Pharmacogenomics J; 2015 Aug; 15(4):354-62. PubMed ID: 25532759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic Profile of Colorectal Cancer: Interplay Between Primary Tumor Location and KRAS Status.
    Zihui Yong Z; Ching GTH; Ching MTC
    J Surg Res; 2020 Feb; 246():325-334. PubMed ID: 30737098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating
    Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
    World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer.
    Eilertsen IA; Sveen A; Strømme JM; Skotheim RI; Nesbakken A; Lothe RA
    Int J Cancer; 2019 Feb; 144(4):841-847. PubMed ID: 30121958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinicopathological features and
    Xue X; Li X; Pan Z; Zhao L; Ding Y
    Int J Clin Exp Pathol; 2017; 10(11):11353-11359. PubMed ID: 31966490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
    Reggiani Bonetti L; Barresi V; Maiorana A; Manfredini S; Caprera C; Bettelli S
    Dis Markers; 2018; 2018():2959801. PubMed ID: 30018674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study.
    Chen KH; Shao YY; Chen HM; Lin YL; Lin ZZ; Lai MS; Cheng AL; Yeh KH
    BMC Cancer; 2016 May; 16():327. PubMed ID: 27221731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical baseline and prognostic difference of platelet lymphocyte ratio (PLR) in right-sided and let-sided colon cancers.
    Yang L; He W; Kong P; Jiang C; Yang Q; Xie Q; Xia LP
    BMC Cancer; 2017 Dec; 17(1):873. PubMed ID: 29262803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status.
    Akman T; Oztop I; Baskin Y; Unek IT; Demir N; Ellidokuz H; Yilmaz AU
    J Cancer Res Ther; 2016; 12(1):96-102. PubMed ID: 27072218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological and molecular differences between right-sided and left-sided colorectal cancer in Japanese patients.
    Natsume S; Yamaguchi T; Takao M; Iijima T; Wakaume R; Takahashi K; Matsumoto H; Nakano D; Horiguchi SI; Koizumi K; Miyaki M
    Jpn J Clin Oncol; 2018 Jul; 48(7):609-618. PubMed ID: 29767751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
    Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.
    Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D
    Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.